Garde Capital Inc. bought a new position in shares of Zoetis Inc (NYSE:ZTS) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 6,570 shares of the company’s stock, valued at approximately $419,000.
A number of other institutional investors and hedge funds also recently modified their holdings of the business. Dynamic Technology Lab Private Ltd lifted its holdings in shares of Zoetis by 7.3% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 5,901 shares of the company’s stock valued at $368,000 after purchasing an additional 401 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Zoetis by 8.2% during the 2nd quarter. Wells Fargo & Company MN now owns 5,113,948 shares of the company’s stock valued at $319,008,000 after purchasing an additional 389,260 shares in the last quarter. Swiss National Bank lifted its holdings in shares of Zoetis by 8.1% during the 2nd quarter. Swiss National Bank now owns 1,796,380 shares of the company’s stock valued at $112,058,000 after purchasing an additional 133,900 shares in the last quarter. Balyasny Asset Management LLC lifted its holdings in shares of Zoetis by 55.5% during the 2nd quarter. Balyasny Asset Management LLC now owns 44,330 shares of the company’s stock valued at $2,765,000 after purchasing an additional 15,830 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in shares of Zoetis by 13.9% during the 2nd quarter. Victory Capital Management Inc. now owns 277,641 shares of the company’s stock valued at $17,320,000 after purchasing an additional 33,894 shares in the last quarter. Hedge funds and other institutional investors own 93.33% of the company’s stock.
A number of equities research analysts recently issued reports on the company. Cantor Fitzgerald set a $80.00 target price on Zoetis and gave the company a “buy” rating in a research report on Tuesday. Morgan Stanley raised Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 target price on the stock in a research report on Wednesday, November 29th. UBS reissued a “neutral” rating on shares of Zoetis in a research report on Friday, November 24th. Cowen set a $80.00 target price on Zoetis and gave the company a “buy” rating in a research report on Friday, November 17th. Finally, Jefferies Group reissued a “buy” rating on shares of Zoetis in a research report on Friday, November 10th. One analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company. Zoetis presently has an average rating of “Buy” and an average price target of $68.53.
Zoetis Inc (NYSE ZTS) traded up $0.15 during trading hours on Thursday, hitting $72.38. The company’s stock had a trading volume of 1,595,000 shares, compared to its average volume of 2,752,414. The firm has a market cap of $35,270.00, a price-to-earnings ratio of 33.13, a price-to-earnings-growth ratio of 2.17 and a beta of 1.06. Zoetis Inc has a 52-week low of $50.57 and a 52-week high of $72.99. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.02. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The business’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.52 EPS. equities research analysts forecast that Zoetis Inc will post 2.37 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be given a dividend of $0.126 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date is Thursday, January 18th. This represents a $0.50 annualized dividend and a dividend yield of 0.70%. Zoetis’s payout ratio is 22.11%.
TRADEMARK VIOLATION NOTICE: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/14/garde-capital-inc-takes-position-in-zoetis-inc-zts.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.